In a nut shell - Re-post from Gotham Bay Group, IH
Post# of 1481
(Total Views: 4210)
Posted On: 04/20/2017 10:16:28 PM
In a nut shell - Re-post from Gotham Bay Group, IHUB:
In a nut shell this is what you are looking at in my opinion. MYDX has multiple revenue generating products. They have eliminated the majority of toxic debt. They have decrease operating costs to a bare minimum. In doing so they have negotiated the outsourcing of production, R&D, shipping, service, sales and marketing. This was done through contracting so debt is only accrued as services are rendered. Many of these contracts allow for 60 plus days before payment is due to allow revenue to catch-up with expenditure. They are concentrating efforts on the core products in play that the 26 million in accumulated debt bought. Data will be the key revenue producer considering it will take next to nothing from here on to maintain and license the use. This would generate a constant cash flow which is something conventional financiers like. Analyzers will sell and as the sales increase production costs will decrease and purchase price will follow. When BudGenius deal is consummated this will allow increased data to existing MYDX database combined with POS capabilities for that data. With Torque Research & Development, Inc, R&D continues as does new product development. Finally Libre Design is contracted to market the MYDX brand. They have branding and marketing experience and most importantly this area of the company will not be stagnate with this agreement.
Yes there are a lot of numbers in the annual but from an investor and business point of view that is historical reference and nothing can change it now. But what can make future quarters acceptable is the plan moving forward which is sound at this point. Mr. Yazbeck is heavily vested in this as apparent from the filing which should be a sign of his dedication and faith in MYDX success.
Any man that lands on an island so intent on conquering he is willing to burn his ships of retreat is a man worth following.
This is of special importance:
“MyDx plans to evaluate 510K approval process to leverage its consumer products and the ability of insurance companies to support sales of its smart devices and generate HIPPA compliant crowdsourced data.” In simple terms they are going to try and make this for medical cannabis patients what a glucose tester is to a diabetic.
In a nut shell this is what you are looking at in my opinion. MYDX has multiple revenue generating products. They have eliminated the majority of toxic debt. They have decrease operating costs to a bare minimum. In doing so they have negotiated the outsourcing of production, R&D, shipping, service, sales and marketing. This was done through contracting so debt is only accrued as services are rendered. Many of these contracts allow for 60 plus days before payment is due to allow revenue to catch-up with expenditure. They are concentrating efforts on the core products in play that the 26 million in accumulated debt bought. Data will be the key revenue producer considering it will take next to nothing from here on to maintain and license the use. This would generate a constant cash flow which is something conventional financiers like. Analyzers will sell and as the sales increase production costs will decrease and purchase price will follow. When BudGenius deal is consummated this will allow increased data to existing MYDX database combined with POS capabilities for that data. With Torque Research & Development, Inc, R&D continues as does new product development. Finally Libre Design is contracted to market the MYDX brand. They have branding and marketing experience and most importantly this area of the company will not be stagnate with this agreement.
Yes there are a lot of numbers in the annual but from an investor and business point of view that is historical reference and nothing can change it now. But what can make future quarters acceptable is the plan moving forward which is sound at this point. Mr. Yazbeck is heavily vested in this as apparent from the filing which should be a sign of his dedication and faith in MYDX success.
Any man that lands on an island so intent on conquering he is willing to burn his ships of retreat is a man worth following.
This is of special importance:
“MyDx plans to evaluate 510K approval process to leverage its consumer products and the ability of insurance companies to support sales of its smart devices and generate HIPPA compliant crowdsourced data.” In simple terms they are going to try and make this for medical cannabis patients what a glucose tester is to a diabetic.
(1)
(0)MyDx, Inc. (MYDX) Stock Research Links
Scroll down for more posts ▼